Remove

INFORMATION DISCLOSURE
STATEMENT BY APPLICANT
(Not for submission under 37 CFR 1.99)

Application Number		09753537
Filing Date		2001-01-02
First Named Inventor David		L. Multer et al.
Art Unit		2165
Examiner Name Abel		Jalil, Neveen
Attorney Docket Number		FUSI-04105

	U.S.FATENTS							
Examiner Initial*	Cite No	Patent Number	Kind Code ¹	Issue Date	Name of Patentee or Applicant of cited Document	Pages,Columns,Lines where Relevant Passages or Relevant Figures Appear		
	1	5832520		1998-11-03	Miller			
2 6505216		B1	2003-01-07	Schutzman et al.				
	3 7158805		B1	2007-01-02	Park et al.			
	4	7853664	B1	2010-12-14	Wang et al.			
If you wisl	h to add	additional U.S. Pater	t citatio	n information pl	ease click the Add button.	Add		
	U.S.PATENT APPLICATION PUBLICATIONS Remove							
Examiner Initial*	Cite No	Publication Number	Kind Code ¹	Publication Date	Name of Patentee or Applicant of cited Document	Pages,Columns,Lines where Relevant Passages or Relevant Figures Appear		
1		20010034737	A1	2001-10-25	Cane et al.			
	2	20040267390	A1	2004-12-30	Ben-Yaacov et al.			

U.S.PATENTS

INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Not for submission under 37 CFR 1.99)

Application Number			09753537	
	Filing Date		2001-01-02	
	First Named Inventor	David	L. Multer et al.	
	Art Unit		2165	
	Examiner Name	Abel .	Jalii, Neveen	
	Attack on Dealest North	or	EURI 04105	

	3		20050096975	A1	2005-05	-05	Moshe			
	4		20050144200	A1	2005-06	i-30	Hesselink et al			
	5		20060095397	A1	2006-05-04		Torres et al.			
	6		20070220419	A1	2007-09	-20	Stibel et al			
	7		20090037828	A1	2009-02-05		Waite et al.			
	8		20090138546	A1	2009-05	i-28	Cruzada			
If you wish to add additional U.S. Published Application citation information please click the Add button. Add										
					FOREIG	SN PAT	ENT DOCUM	ENTS	Remove	
Examiner Initial*	niner Cite Foreign Document Country Kind No Number ³ Code ² j Code ⁴		Publication Date	Name of Patente Applicant of cited Document	Pages, Columns, Lines where Relevant Passages or Relevant Figures Appear	Tc				
	1									
If you wish to add additional Foreign Patent Document citation information please click the Add button Add										
				NON	I-PATEN	NT LITE	RATURE DO	CUMENTS	Remove	
Examiner Initials*	Cite No	(bo	clude name of the au ook, magazine, journ blisher, city and/or o	nal, seri	al, symp	osium,	catalog, etc), o		riate), title of the item issue number(s),	T5

1	NGUYEN, Phong H., Examiner Group Art Unit 2162, United States Patent & Trademark Office, Office Acton mailed July 20, 2011, for Application No. 12/037,509, Altorney Docket No. FUSI-04110, 24 pgs.	

If you wish to add additional non-patent literature document citation information please click the Add button Add

EXAMINER SIGNATURE

Examiner Signature Date Considered

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through a citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

16ee Kinz Codes of USPTO Patent Documents at years LISETIO_COL or MISCP 901.6. ² Enter office that issued the document, by the No-letter code (MIPO) standard 573. ³ The Juspance patent obcuments, by an advantage of the page of the Emptor that prepare has been under or the patent document. ⁴ Nort of countert, by the appropriate symbols as indicated on the document will be part of the Emptor that page of th

INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Not for submission under 37 CFR 1.99)

Application Number		09753537	
Filing Date		2001-01-02	
First Named Inventor David		L. Multer et al.	
Art Unit		2165	
Examiner Name	Abel .	Jali, Neveen	
Attorney Docket Number		FUSI-04105	

CERTIFICATION STATEMENT

Please see 37	CFR 1.9	7 and	1.98 to make the	appropriate	selection(s):
---------------	---------	-------	------------------	-------------	---------------

That each item of information contained in the information disclosure statement was first cited in any communication from a foreign patent office in a counterpart foreign application not more than three months prior to the filing of the information disclosure statement. See 37 CFR 1.97(e)(1).

OR

That no item of information contained in the information disclosure statement was cited in a communication from a foreign patent office in a counterpart foreign application, and, to the knowledge of the person signing the certification after making reasonable inquiry, no item of information contained in the information disclosure statement was known to any individual designated in 37 CFR 1,59(c) more than three months prior to the filing of the information disclosure statement. See 37 CFR 1,57(e)(c).

- See attached certification statement.
- Fee set forth in 37 CFR 1.17 (p) has been submitted herewith.

David A Hill

_ ...

Name/Print

SIGNATURE

A signature of the applicant or representative is required in accordance with CFR 1.33, 10.18. Please see CFR 1.4(d) for the form of the signature.

Signature	/David A. Hill/	Date (YYYY-MM-DD)	2011-09-20					

This collection of information is required by 37 CR1 137 and 138. The information is required to obtain or retain a benefit by the public which is for lie and by the USPTO to process) an application. Confidentiality is governed by \$5 U.S. C.12 CAI AT 37 CR1.

1.14. This collection is estimated to take 1 hour to complete, including gathering, preparing and submitting the completed application from to the USPTO. There will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Operatment of Commence 7. P. Data 1456, Alexandria, VA 2211-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1456, Alexandria, VA 2211-1450.

Registration Number

44 153

Privacy Act Statement

The Privacy Act of 1974 (P. L. 95.79) requires that you be given certain information in connection with your submission of the attached form related to a patient application or patient. Accordingly, pursuant to the requirements of the Act, please be advised that: (1) the general authority for the collection of this information is 35 U.S.C. 2(b)(2); (2) furnishing of the information solicide to is coluntary, and (3) the principal purpose for which the information is used by the U.S. Patient and Trademan KORice is to process andior examine your submission related to a patient application or patient. If you do not furnish the requested process andior examine your submission related to a patient application or patient. If you do not furnish the requested required to the procession of the submission, which may result in fearning-time of proceedings or a banderiness of the separation of the submission.

The information provided by you in this form will be subject to the following routine uses:

- The information on this form will be treated confidentially to the extent allowed under the Freedom of Information Act (5 U.S.C. 552) and the Privacy Act (5 U.S.C. 552a). Records from this system of records may be disclosed to the Department of Justice to determine whether the Freedom of Information Act requires disclosure of these record s.
- A record from this system of records may be disclosed, as a routine use, in the course of presenting evidence to a court, magistrate, or administrative tribunal, including disclosures to opposing counsel in the course of settlement neodiations.
- A record in this system of records may be disclosed, as a routine use, to a Member of Congress submitting a request involving an individual, to whom the record pertains, when the individual has requested assistance from the Member with respect to the subiect matter of the record.
- A record in this system of records may be disclosed, as a routine use, to a contractor of the Agency having need for the information in order to perform a contract. Recipients of information shall be required to comply with the requirements of the Privacy Act of 1974. as amended, oursuant to 5 U.S.C. 552a(m).
- A record related to an International Application filed under the Patent Cooperation Treaty in this system of records
 may be disclosed, as a routine use, to the International Bureau of the World Intellectual Property Organization, pursuant
 to the Patent Cooperation Treaty.
- A record in this system of records may be disclosed, as a routine use, to another federal agency for purposes of National Security review (35 U.S.C. 181) and for review pursuant to the Atomic Energy Act (42 U.S.C. 218(c)).
- 7. A record from this system of records may be disclosed, as a routine use, to the Administrator, General Services, or hisher designed, cuting an inspection of records conducted by GSA is part of that apency's responsibility to recommend improvements in records management practices and programs, under authority of 4 U.S.C. 2904 and 2906. Such disclosure shall be made in accordance with the GSA regulations governing inspection of records for this purpose, and any other relevant (i.e., GSA or Commerce) directive. Such disclosure shall not be used to make determinations abavit individuals.
- A record from this system of records may be disclosed, as a routine use, to the public after either publication of
 the application presume to 58 U.S. C. 159 or issuance of a patient pursuant to 55 U.S. C. 151. Further, a record
 may be disclosed, subject to the limitations of 37 CFR 1.14, as a routine use, to the public fifthe record was filled in
 an application which became abandoned or in which the proceedings were terminated and which application is
 referenced by either a published application, one of public inspections or an issued patient.
- A record from this system of records may be disclosed, as a routine use, to a Federal, State, or local law enforcement agency, if the USPTO becomes aware of a violation or potential violation of law or regulation.